A first-in-human phase 1 study of cavrotolimod, a TLR9 agonist spherical nucleic acid, in healthy participants: Evidence of immune activation.

Front Immunol · 2022 · PMC9792500 · PMID 36582243

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although these fold changes were relatively large, they were not dose proportional, did not reach statistical significance, and represented only a small fraction (<2%) of the total number of the total monocytes.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.